European Biotech Acquisition Corp. (EBAC) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
EPFL INNOVATION PARK BUILDING LAUSANNE, 1015 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 677 - Blank Checks (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 868,280 | |||
| Cash and cash equivalents | 868,280 | |||
| Prepaid expense | 48,190 | |||
| Total current assets: | 916,470 | |||
| Noncurrent Assets | ||||
| Asset, held-in-trust | 127,556,289 | |||
| Total noncurrent assets: | 127,556,289 | |||
| TOTAL ASSETS: | 128,472,759 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 505,201 | |||
| Accounts payable | 57,906 | |||
| Accrued liabilities | 447,295 | |||
| Other undisclosed current liabilities | ||||
| Total current liabilities: | 505,201 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 2,641,980 | |||
| Deferred compensation liability, classified | ||||
| Derivative instruments and hedges, liabilities | 2,641,980 | |||
| Other undisclosed noncurrent liabilities | 4,464,174 | |||
| Total noncurrent liabilities: | 7,106,154 | |||
| Total liabilities: | 7,611,355 | |||
| Temporary equity, carrying amount | 127,547,840 | |||
| Equity | ||||
| Equity, attributable to parent, including: | (6,686,436) | |||
| Accumulated deficit | (6,686,801) | |||
| Other undisclosed equity, attributable to parent | 365 | |||
| Total equity: | (6,686,436) | |||
| TOTAL LIABILITIES AND EQUITY: | 128,472,759 | |||
Income Statement (P&L) (USD)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Operating expenses | (912,095) | ||
| Other undisclosed operating loss | (187,742) | ||
| Operating loss: | (1,099,837) | ||
| Nonoperating income (Investment Income, Nonoperating) | 8,445 | ||
| Loss from continuing operations before equity method investments, income taxes: | (1,091,392) | ||
| Other undisclosed income from continuing operations before income taxes | |||
| Income (loss) from continuing operations: | (1,091,392) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (1,091,392) | |
| Net income (loss): | (1,091,392) | ||
| Other undisclosed net income attributable to parent | 2,570,064 | ||
| Net income available to common stockholders, diluted: | 1,478,672 | ||
Comprehensive Income (USD)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Net income (loss): | (1,091,392) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,091,392) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.